Results 91 to 100 of about 198,039 (308)

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report

Respiratory Medicine Case Reports
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events.
Tomoya Harada, Naoki Uetani, Genki Inui, Hiroki Ishikawa, Yoshihiro Funaki, Miki Takata, Ryota Okazaki, Kosuke Yamaguchi, Masato Morita, Shin Kitatani, Akira Yamasaki   +10 more
doaj   +1 more source

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial

BMJ Open, 2020
Background Pembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC).
Haiying Ding, Wenxiu Xin, Qilu Fang, Xiaowei Zheng, Yinghui Tong, Gaoqi Xu, Guonong Yang   +6 more
doaj   +1 more source

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. [PDF]

, 2019
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to ...
Adashek, Jacob J, Galanina, Natalie, Junior, Pedro Nazareth Aguiar, Kurzrock, Razelle   +3 more
core  

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. [PDF]

, 2018
BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319).MethodsPatients received ...
Arance, Ana S, Brown, Ewan, Butler, Marcus, Daud, Adil, Ebbinghaus, Scot, Hamid, Omid, Hodi, F Stephen, Hoeller, Christoph, Ibrahim, Nageatte, Long, Jianmin, Mortier, Laurent, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Walpole, Euan   +14 more
core   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors

Nature Communications
Neoadjuvant immunotherapy can induce pathologic complete response (pCR) in patients with localized deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors.
Michael LaPelusa, Wei Qiao, Bryan Iorgulescu, Francis San Lucas, Keyur Patel, Deepak Bhamidipati, Jane Varkey Thomas, Nancy You, Wai Chin Foo, Dipen Maru, Selvi Thirumurthi, Van Morris, Scott Kopetz, Michael Overman, Kaysia Ludford   +14 more
doaj   +1 more source

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Dermatology Practical & Conceptual
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Yu Du, Zhonghui Qi, Xianbin Liang , Jie Dai, Xiaoting Wei , Xue Bai , Lili Mao, Zhihong Chi , Chuanliang Cui, Bin Lian, Bixia Tang , Xuan Wang , Yu Chen , Jun Guo , Lu Si   +14 more
doaj   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

Blood Advances
: Favezelimab plus pembrolizumab had promising efficacy in anti–programmed cell death protein 1 (PD-1)–refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution
Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian G. Topp, Pallavi Pillai, Alex F. Herrera   +8 more
doaj   +1 more source